Figure 4 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Year: 2024
Type: other
Abstract: Analysis of treatment-associated outcomes and effect of mutation status among patients in Caris CODEai clinico-genomic database. A and B, Kaplan–Meier analysis comparing posttreatment OS between patients with STK11-mutated (mut, blue lines) and STK11-wild type (wt, red lines) NSCLC treated with (A) carboplatin (no pembrolizumab) and (B) pembrolizumab (no carboplatin). C and D, Kaplan–Meier analysis comparing (C) posttreatment OS and (D) TOT between patients treated with pemetrexed (blue lines) and osimertinib (red lines) for EGFR-mut NSCLC. E and F, Kaplan–Meier analysis comparing posttreatment OS between patients with EGFR-mut (blue lines) and EGFR-wt (red lines) NSCLC treated with (E) osimertinib or (F) pemetrexed. G and H, Kaplan–Meier analysis comparing (G) posttreatment OS and (H) TOT between patients treated with fluorouracil (blue lines) and capecitabine (red lines) for colorectal cancer.
Authors: Elisabeth Heath, Gregory Dyson, Jennifer R. Ribeiro, Joanne Xiu, Kelsey Poorman, Hirva Mamdani, Mohammed N. Al-Hallak, Anthony F. Shields, Jailan A. Elayoubi, Ira S. Winer, Frank C. Cackowski, Gary A. Puckrein, Gilberto de Lima Lopes, Nathaniel Jones, Ralph J. Hauke, Samuel A. Kareff, Milan Radovich, George W. Sledge, David B. Spetzler, Gregory A. Vidal, John L. Marshall
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4403136060